The primary objective of this study is to determine whether the investigational transendocardial delivery of allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective for chronic heart failure due to LV systolic dysfunction.
CRITERIA LIST/ QUALIFICATIONS:
The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at least 6 months.
The patient is on stable, optimally tolerated dosages of HF therapies including beta-blockers (approved for country-specific usage), angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone antagonists, without change in dose for at least 1 month before study intervention.
The patient is on a stable, outpatient, oral diuretic dosing regimen in which the patient remains clinically stable during screening.